A 4-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Efficacy of EVT 101 as Monotherapy in Patients With Treatment-Resistant Major Depression

Trial Profile

A 4-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Efficacy of EVT 101 as Monotherapy in Patients With Treatment-Resistant Major Depression

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs EVT 101 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 23 May 2011 Status changed from recruiting to discontinued.
    • 18 May 2011 The trial was voluntarily terminated due to difficulties in recruiting patients under the study protocol
    • 28 Mar 2011 Planned End Date changed from 1 Sep 2011 to 1 Sep 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top